Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.

Venturelli E, Orenti A, Fabricio ASC, Garrone G, Agresti R, Paolini B, Bonini C, Gion M, Berrino F, Desmedt C, Coradini D, Biganzoli E.

BMC Cancer. 2018 Sep 10;18(1):876. doi: 10.1186/s12885-018-4799-2.

2.

Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.

Venturelli E, Orenti A, Fabricio ASC, Garrone G, Agresti R, Paolini B, Bonini C, Gion M, Berrino F, Desmedt C, Coradini D, Biganzoli E.

BMC Cancer. 2018 Jun 13;18(1):651. doi: 10.1186/s12885-018-4558-4. Erratum in: BMC Cancer. 2018 Sep 10;18(1):876.

3.

Serum levels of testosterone and SHBG in association with body mass index improve the predictive capability of consolidate tumor biomarkers in pre- and postmenopausal breast cancer patients.

Coradini D, Orenti A, Venturelli E, Cavalleri A, Biganzoli E, Oriana S.

Jpn J Clin Oncol. 2018 Apr 1;48(4):308-316. doi: 10.1093/jjco/hyy012.

PMID:
29474646
4.

Epithelial cell identity in hyperplastic precursors of breast cancer.

Coradini D, Boracchi P, Oriana S, Biganzoli E, Ambrogi F.

Chin J Cancer. 2015 Mar 5;34(3):121-9. doi: 10.1186/s40880-015-0004-z.

5.

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.

Coradini D, Biganzoli E, Ardoino I, Ambrogi F, Boracchi P, Demicheli R, Daidone MG, Moliterni A.

Breast. 2015 Jun;24(3):294-7. doi: 10.1016/j.breast.2015.01.007. Epub 2015 Feb 16.

PMID:
25698149
6.

Differential expression of genes involved in the epigenetic regulation of cell identity in normal human mammary cell commitment and differentiation.

Coradini D, Boracchi P, Oriana S, Biganzoli E, Ambrogi F.

Chin J Cancer. 2014 Oct;33(10):501-10. doi: 10.5732/cjc.014.10066. Epub 2014 Sep 16.

7.

Cell identity disruption in breast cancer precursors.

Coradini D, Boracchi P, Oriana S, Biganzoli E, Ambrogi F.

Anticancer Res. 2014 Mar;34(3):1307-19.

PMID:
24596378
8.

The role of maintenance proteins in the preservation of epithelial cell identity during mammary gland remodeling and breast cancer initiation.

Coradini D, Oriana S.

Chin J Cancer. 2014 Feb;33(2):51-67. doi: 10.5732/cjc.013.10040. Epub 2013 Jul 12. Review.

9.

Comments on the use of a single or multiple probe-set approach for microarray-based analyses of routine molecular markers in breast cancer.

Coradini D, Ambrogi F, Boracchi P.

Breast Cancer Res Treat. 2013 Jan;137(2):647-9. doi: 10.1007/s10549-012-2379-8. Epub 2012 Dec 19. No abstract available.

PMID:
23250548
10.

Cytoplasmic Trop-1/Ep-CAM overexpression is associated with a favorable outcome in node-positive breast cancer.

Alberti S, Ambrogi F, Boracchi P, Fornili M, Querzoli P, Pedriali M, La Sorda R, Lattanzio R, Tripaldi R, Piantelli M, Biganzoli E, Coradini D.

Jpn J Clin Oncol. 2012 Dec;42(12):1128-37. doi: 10.1093/jjco/hys159. Epub 2012 Oct 16.

PMID:
23072840
11.

TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes.

Coradini D, Fornili M, Ambrogi F, Boracchi P, Biganzoli E.

J Biomed Biotechnol. 2012;2012:254085. doi: 10.1155/2012/254085. Epub 2012 Jul 30.

12.

Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ.

Coradini D, Boracchi P, Ambrogi F, Biganzoli E, Oriana S.

Int J Surg Oncol. 2012;2012:984346. doi: 10.1155/2012/984346. Epub 2012 Apr 2.

13.

Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment.

Coradini D, Casarsa C, Oriana S.

Acta Pharmacol Sin. 2011 May;32(5):552-64. doi: 10.1038/aps.2011.20. Epub 2011 Apr 18. Review.

14.

Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma.

Casarsa C, Bassani N, Ambrogi F, Zabucchi G, Boracchi P, Biganzoli E, Coradini D.

Cancer Lett. 2011 Mar 28;302(2):136-43. doi: 10.1016/j.canlet.2011.01.009.

PMID:
21300430
15.

p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features.

Biganzoli E, Coradini D, Ambrogi F, Garibaldi JM, Lisboa P, Soria D, Green AR, Pedriali M, Piantelli M, Querzoli P, Demicheli R, Boracchi P, Nenci I, Ellis IO, Alberti S.

Jpn J Clin Oncol. 2011 Feb;41(2):172-9. doi: 10.1093/jjco/hyq227. Epub 2011 Jan 2.

PMID:
21199790
16.

Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast.

Demicheli R, Ardoino I, Boracchi P, Coradini D, Agresti R, Ferraris C, Gennaro M, Hrushesky WJ, Biganzoli E.

BMC Cancer. 2010 Nov 30;10:656. doi: 10.1186/1471-2407-10-656.

17.

Gene regulatory networks: a new conceptual framework to analyse breast cancer behaviour.

Demicheli R, Coradini D.

Ann Oncol. 2011 Jun;22(6):1259-65. doi: 10.1093/annonc/mdq546. Epub 2010 Nov 25. Review.

PMID:
21109571
18.

An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer.

Querzoli P, Coradini D, Pedriali M, Boracchi P, Ambrogi F, Raimondi E, La Sorda R, Lattanzio R, Rinaldi R, Lunardi M, Frasson C, Modesti F, Ferretti S, Piantelli M, Iacobelli S, Biganzoli E, Nenci I, Alberti S.

Br J Cancer. 2010 Dec 7;103(12):1835-9. doi: 10.1038/sj.bjc.6605991. Epub 2010 Nov 9.

19.

Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence.

Demicheli R, Biganzoli E, Ardoino I, Boracchi P, Coradini D, Greco M, Moliterni A, Zambetti M, Valagussa P, Gukas ID, Bonadonna G.

Cancer Sci. 2010 Mar;101(3):826-30. doi: 10.1111/j.1349-7006.2009.01472.x. Epub 2009 Dec 16.

20.

Conditional independence relations among biological markers may improve clinical decision as in the case of triple negative breast cancers.

Stefanini FM, Coradini D, Biganzoli E.

BMC Bioinformatics. 2009 Oct 15;10 Suppl 12:S13. doi: 10.1186/1471-2105-10-S12-S13.

21.

A prediction model for breast cancer recurrence after adjuvant hormone therapy.

Boracchi P, Coradini D, Antolini S, Oriana S, Dittadi R, Gion M, Daidone MG, Biganzoli E.

Int J Biol Markers. 2008 Oct-Dec;23(4):199-206.

PMID:
19199266
22.

Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report.

Pellizzaro C, Speranza A, Zorzet S, Crucil I, Sava G, Scarlata I, Cantoni S, Fedeli M, Coradini D.

Pancreas. 2008 May;36(4):e15-23. doi: 10.1097/MPA.0b013e31816705bc.

PMID:
18437074
23.

The controversial clinicobiological role of breast cancer stem cells.

Casarsa C, Oriana S, Coradini D.

J Oncol. 2008;2008:492643. doi: 10.1155/2008/492643. Epub 2009 Mar 19.

24.

Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study.

Martelli G, Miceli R, Costa A, Coradini D, Zurrida S, Piromalli D, Vetrella G, Greco M.

Cancer. 2008 Feb 1;112(3):481-8.

25.

PIK3CA cancer mutations display gender and tissue specificity patterns.

Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D, Daidone MG, Pilotti S, Pierotti MA, Bardelli A.

Hum Mutat. 2008 Feb;29(2):284-8.

PMID:
18022911
26.

Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen.

Coradini D, Gariboldi M, Fedeli M, Pierotti MA, Daidone MG.

Breast Cancer Res Treat. 2008 Sep;111(2):389-90. Epub 2007 Oct 4. No abstract available.

PMID:
17914668
27.

New chemical strategies for overcoming ATRA resistance in APL cells.

Coradini D.

Leuk Res. 2007 Mar;31(3):291-2. Epub 2006 Aug 17. Review. No abstract available.

PMID:
16919330
28.

A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results.

Coradini D, Pellizzaro C, Scarlata I, Zorzet S, Garrovo C, Abolafio G, Speranza A, Fedeli M, Cantoni S, Sava G, Daidone MG, Perbellini A.

Leukemia. 2006 May;20(5):785-92.

PMID:
16525489
29.

Histone deacetylase inhibitors for treatment of hepatocellular carcinoma.

Coradini D, Speranza A.

Acta Pharmacol Sin. 2005 Sep;26(9):1025-33. Review.

30.

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG.

Cancer Res. 2005 Jul 1;65(13):5506-11.

31.

Limits of predictive models using microarray data for breast cancer clinical treatment outcome.

Reid JF, Lusa L, De Cecco L, Coradini D, Veneroni S, Daidone MG, Gariboldi M, Pierotti MA.

J Natl Cancer Inst. 2005 Jun 15;97(12):927-30.

PMID:
15956654
32.

Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells.

Sirchia SM, Ramoscelli L, Grati FR, Barbera F, Coradini D, Rossella F, Porta G, Lesma E, Ruggeri A, Radice P, Simoni G, Miozzo M.

Cancer Res. 2005 Mar 15;65(6):2139-46.

33.

Hyaluronic acid butyric esters in cancer therapy.

Speranza A, Pellizzaro C, Coradini D.

Anticancer Drugs. 2005 Apr;16(4):373-9. Review.

PMID:
15746573
34.

Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.

Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzaro C, Turrin C, Bello M, Cantoni S, Speranza A, Sava G, Mazzi U, Perbellini A.

Clin Cancer Res. 2004 Jul 15;10(14):4822-30.

35.

Biomolecular prognostic factors in breast cancer.

Coradini D, Daidone MG.

Curr Opin Obstet Gynecol. 2004 Feb;16(1):49-55. Review.

PMID:
15128008
36.

Instantaneous response to surgically induced hypoxia of hepatocellular carcinoma.

Coradini D, Costa A, Pellizzaro C, Doci R, Di Rocco M, Gennari L.

J Hepatol. 2004 Mar;40(3):563-5. No abstract available.

PMID:
15123379
37.

Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study.

Coradini D, Pellizzaro C, Abolafio G, Bosco M, Scarlata I, Cantoni S, Stucchi L, Zorzet S, Turrin C, Sava G, Perbellini A, Daidone MG.

Invest New Drugs. 2004 Aug;22(3):207-17.

PMID:
15122068
38.

Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens.

Coradini D, Pellizzaro C, Speranza A, Daidone MG.

Cell Mol Life Sci. 2004 Jan;61(1):76-82.

PMID:
14704855
39.

Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors.

Biganzoli E, Boracchi P, Coradini D, Grazia Daidone M, Marubini E.

Ann Oncol. 2003 Oct;14(10):1484-93.

PMID:
14504047
40.

Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen.

Coradini D, Biganzoli E, Pellizzaro C, Veneroni S, Oriana S, Ambrogi F, Erdas R, Boracchi P, Daidone MG, Marubini E.

Br J Cancer. 2003 Jul 21;89(2):268-70.

41.

Fluctuation of intratumor biological variables as a function of menstrual timing of surgery for breast cancer in premenopausal patients.

Coradini D, Veneroni S, Pellizzaro C, Daidone MG.

Ann Oncol. 2003 Jun;14(6):962-4. No abstract available.

PMID:
12796038
42.

Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.

Cappelletti V, Veneroni S, Coradini D, Oriana S, Tomasic G, Younes M, Daidone MG.

J Natl Cancer Inst. 2003 Apr 16;95(8):629-30. No abstract available.

PMID:
12697859
43.

Primary breast cancer in elderly women: biological profile and relation with clinical outcome.

Daidone MG, Coradini D, Martelli G, Veneroni S.

Crit Rev Oncol Hematol. 2003 Mar;45(3):313-25.

PMID:
12633842
44.

Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla?

Martelli G, Miceli R, De Palo G, Coradini D, Salvadori B, Zucali R, Galante E, Marubini E.

Cancer. 2003 Mar 1;97(5):1156-63.

45.
46.

Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29.

Pellizzaro C, Coradini D, Daidone MG.

Carcinogenesis. 2002 May;23(5):735-40.

PMID:
12016145
47.

The antiproliferative effects of Uncaria tomentosa extracts and fractions on the growth of breast cancer cell line.

Riva L, Coradini D, Di Fronzo G, De Feo V, De Tommasi N, De Simone F, Pizza C.

Anticancer Res. 2001 Jul-Aug;21(4A):2457-61.

PMID:
11724307
48.

Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer.

Coradini D, Boracchi P, Daidone MG, Pellizzaro C, Miodini P, Ammatuna M, Tomasic G, Biganzoli E.

Br J Cancer. 2001 Sep 14;85(6):795-7.

49.

The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-H460 cell proliferation.

Ugazio E, Marengo E, Pellizzaro C, Coradini D, Peira E, Daidone MG, Gasco MR.

Eur J Pharm Biopharm. 2001 Sep;52(2):197-202.

PMID:
11522486
50.

Re: Levels of hypoxia-inducible factor-1alpha during breast carcinogenesis.

Costa A, Coradini D, Carrassi A, Erdas R, Sardella A, Daidone MG.

J Natl Cancer Inst. 2001 Aug 1;93(15):1175-7. No abstract available.

PMID:
11481392

Supplemental Content

Loading ...
Support Center